Want to see SE:XVIVO full AI Analyst Report?
XVIVO Stock Chart & Stats
kr272.40
-kr4.00(-1.61%)
At close: 4:00 PM EDT
kr272.40
-kr4.00(-1.61%)
Day’s Range― - ―
52-Week Rangekr160.10 - kr314.80
Previous CloseN/A
Volume31.51K
Average Volume (3M)99.77K
Market Cap
kr6.36B
Enterprise Valuekr6.74B
Total Cash (Recent Filing)kr313.24M
Total Debt (Recent Filing)kr120.61M
Price to Earnings (P/E)49.4
Beta1.25
Next Earnings
Jan 28, 2027EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.09
Shares Outstanding31,499,470
10 Day Avg. Volume105,388
30 Day Avg. Volume99,772
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)2.78
Price to Sales (P/S)7.24
P/FCF Ratio-38.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.55
Revenue Forecast (FY)kr990.94M
Bulls Say, Bears Say
Bulls Say
Strong Organic GrowthThe broad-based growth indicates rising adoption of XVIVO’s transplantation technologies, especially in thoracic procedures. Strong sales expansion across the first nine months supports operating leverage, funds continued commercial investment, and strengthens the company’s position as transplant centers adopt advanced preservation workflows.
Regulatory And Product ExpansionHeart Assist Transport has achieved meaningful regulatory progress in Europe and the United States, expanding its addressable market beyond existing products. The broad EU indication and accepted U.S. application create a platform for future adoption, although commercialization remains dependent on approvals and reimbursement.
Financial FlexibilityVery low leverage gives XVIVO substantial financial flexibility to fund clinical trials, regulatory work, commercial expansion, and production capacity without relying heavily on debt. Recent positive cash generation further supports internal funding, even though the company’s longer-term cash-flow record has been uneven.
Bears Say
Component ConstraintsComponent shortages directly limit the company’s ability to convert customer demand into revenue, particularly in kidney products. Although management describes the issue as temporary, continued constraints over coming quarters could delay growth, weaken customer availability, and postpone the return to higher growth rates.
Margin And Services PressureWeak services revenue and negative services margin show that expansion of the surgical team and slower contract conversion are currently dilutive. Planned sales-force investment for future launches may create additional near-term margin pressure, making profitability less predictable while the growth infrastructure is built.
Customer Concentration RiskA major customer’s planned partial move to an internal EVLP platform could reduce thoracic revenue and utilization of XVIVO’s products. Management expects new-customer growth to offset the impact, but the transition creates execution risk because replacement volume must be developed before the customer loss is fully absorbed.
Xvivo Perfusion AB News
XVIVO FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.10 and its highest was kr314.80 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is kr6.36B.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Jan 28, 2027 which is in 92 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Oct 22, 2026. The company reported kr1.41 earnings per share for the quarter, beating the consensus estimate of kr0.651 by kr0.759.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.87.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of kr1.41 in its last earnings report, beating expectations of kr0.651. Following the earnings report the stock price went down -1.412%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in SE:XVIVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
XVIVO Company Deck
XVIVO Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.View all SE:XVIVO earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Getinge
―
Vitrolife AB
―
BICO Group AB Class B
―
SciBase Holding AB
―
Sedana Medical AB
―








